Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
Last trade$1.71
Day change-$0.045 (-2.57%)
Day range$1.66 – $1.88
Volume95,334
Market cap$37M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$36.81M
Price / earnings
—
Price / book
0.66×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.53×
Profitability
Earnings per share
-$1.02
Return on assets
-37.11%
Return on equity
-38.6%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
13.61×
Quick ratio
13.61×
Cash ratio
13.2×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$8.93M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for GRCE, quarterly periods
Line item
Q2 FY2027 Sep 30, 2026
Q1 FY2027 Jun 30, 2026
Q4 FY2026 Mar 31, 2026
Q3 FY2026 Dec 31, 2025
Q2 FY2026 Sep 30, 2025
Q1 FY2026 Jun 30, 2025
Q4 FY2025 Mar 31, 2025
Q3 FY2025 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.41M
$1.69M
$2.59M
$1.99M
$1.96M
$2.14M
$1.55M
$1.51M
Research and development
$885K
$697K
$420K
$462K
$568K
$955K
$1.63M
$2.19M
Total operating expenses
$2.29M
$15.92M
$3.01M
$2.45M
$2.53M
$3.09M
$3.18M
$3.7M
Operating income
-$2.29M
-$15.92M
-$3.01M
-$2.45M
-$2.53M
-$3.09M
-$3.18M
-$3.7M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$2.14M
-$15.79M
-$2.88M
-$2.32M
-$938K
-$3.36M
-$382K
-$4.76M
Income taxes
-$8K
$0
-$1.7M
$0
$0
$0
-$1.02M
-$605K
Net income
-$2.13M
-$15.79M
-$1.18M
-$2.32M
-$938K
-$3.36M
$636K
-$4.16M
Net income attributable to common shareholders
-$2.13M
-$15.79M
-$1.18M
-$2.32M
-$938K
-$3.36M
$636K
-$4.16M
EBITDA
-$2.29M
-$2.38M
-$3.01M
-$2.45M
-$2.53M
-$3.09M
-$3.18M
-$3.7M
Basic earnings per share
-$0.11
-$0.91
-$0.07
-$0.14
-$0.06
-$0.21
$0.04
-$0.36
Diluted earnings per share
-$0.11
-$0.91
-$0.07
-$0.14
-$0.06
-$0.21
$0.04
-$0.36
Recent news
Company coverage with links to the original publishers.
Grace Therapeutics (GRCE), a late-stage biopharma company developing GTx-104 for aneurysmal subarachnoid hemorrhage, announced its participation in BIO-Europe 2026 and the Craig-Hallum 17th Annual Alpha Select Conference in November 2026. CEO Prashant Kohli will meet with industry representatives and investors at these events.
Law firm Holzer & Holzer is investigating whether Grace Therapeutics complied with federal securities laws following the FDA's issuance of a Complete Response Letter for its GTx-104 drug application on April 23, 2026. The CRL cited issues with packaging leachables data, non-clinical toxicology assessments, and manufacturing deficiencies, causing the company's stock price to decline. The firm is seeking investors who suffered losses to join potential litigation.
Grace Therapeutics announced that its STRIVE-ON Phase 3 trial results for GTx-104, an injectable nimodipine formulation for aneurysmal subarachnoid hemorrhage (aSAH), have been accepted for presentation at the 2026 American Academy of Neurology annual meeting. The trial met its primary endpoint, showing GTx-104 reduced clinically significant hypotension by 19% compared to oral nimodipine (28% vs 35%), with 54% of patients achieving 95%+ relative dose intensity versus only 8% on oral nimodipine. Additional benefits included fewer ICU readmissions and better functional outcomes at 90 days.
Grace Therapeutics announced that CEO Prashant Kohli will present at TD Cowen's 46th Annual Health Care Conference on March 4, 2026. The company also revealed that the FDA established April 23, 2026 as the PDUFA target date for review of GTx-104, an IV infusion formulation of nimodipine being developed for aneurysmal subarachnoid hemorrhage (aSAH) treatment.
Grace Therapeutics announced that its Phase 3 STRIVE-ON trial for GTx-104, a novel injectable formulation of nimodipine, met its primary endpoint and showed evidence of clinical benefit over oral nimodipine in aSAH patients. The company plans to submit a New Drug Application (NDA) for GTx-104 in the first half of 2025.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.